210
Participants
Start Date
November 13, 2023
Primary Completion Date
October 31, 2026
Study Completion Date
September 30, 2027
DOR/DTG/3TC
Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.
Inselgruppe AG, Bern
Cantonal Hospital Aarau, Aarau
University Hospital Basel, Basel
University Hospital Geneva, Geneva
University of Lausanne Hospitals, Lausanne
Lugano Regional Hospital Lugano, Lugano
Cantonal Hospital of St. Gallen, Sankt Gallen
University Hospital Zürich, Zurich
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
OTHER
University of Bern
OTHER
Insel Gruppe AG, University Hospital Bern
OTHER